Health outcome studies constitute a new and emerging field of multiple sclerosis research. All studies performed so far underscore the importance of indirect cost in multiple sclerosis.
However, the marked differences in cost-effectiveness studies illustrate that the method of economic modeling has considerable impact on the results of these studies, which need
standardization in order to evaluate properly the economic consequences of new and expensive therapies in multiple sclerosis.
- The DNA Copy Number of Human Endogenous Retrovirus-W (MSRV-Type) Is Increased in Multiple Sclerosis Patients and Is Influenced by Gender and Disease Severity (blogsclerosismultiple.wordpress.com)
- Most multiple sclerosis patients in UK ‘receiving inadequate care’ (guardian.co.uk)
- $18 Million In New Research Projects Launched To Stop Multiple Sclerosis (blogsclerosismultiple.wordpress.com)